It is well established that low high-density lipoprotein (HDL) cholesterol is a risk factor for coronary artery disease (CAD). Growing evidence from epidemiologic as well as intervention studies have identified that a lo...
Inhibitors of cholesterol ester transfer protein (CETP) have the capacity to increase plasma high-density lipoprotein cholesterol to unprecedented levels. Still, hopes that CETP inhibition could reduce atherosclerosis we...
Inhibition of the cholesteryl ester transfer protein (CETP), a plasma protein that normally transfers cholesterol from the protective high-density lipoprotein (HDL) fraction to the atherogenic low-density lipoprotein (LD...
Increasing interest has focused on the potential clinical utility of therapies that promote the biologic activity of high-density lipoprotein (HDL). Arterial wall imaging has been used in clinical trials to demonstrate t...
Cholesterol ester transfer protein (CETP) deficiency or inhibition results in dramatic elevations of high-density lipoprotein (HDL) levels, but there has been concern that HDL might be dysfunctional in its ability to pro...
Despite contemporary therapies for acute coronary syndrome (ACS), rates of morbidity and mortality remain high. Low levels of high-density lipoprotein (HDL) cholesterol are common among patients with ACS and predict risk...
As the significance of treating coronary artery disease (CAD) remains a high priority in reducing morbidity and mortality worldwide, newer treatment strategies continue to evolve. The efficacy of statin therapy in reduci...
The risk for coronary artery disease (CAD) is inversely correlated with high-density lipoprotein (HDL) cholesterol plasma levels. These plasma HDL cholesterol levels are influenced by the activity of a number of enzymes ...